HALOZYME THERAPEUTICS, INC.
HaloZyme Therapeutics, Inc. (NASDAQ: HALO) operates as a biopharmaceutical company focused on developing and commercializing innovative medicines and drug delivery technologies. The company's website is www.halozyme.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What HALOZYME THERAPEUTICS, INC. does
In the company’s own words
HaloZyme Therapeutics, Inc. (NASDAQ: HALO) operates as a biopharmaceutical company focused on developing and commercializing innovative medicines and drug delivery technologies. The company's website is www.halozyme.com.
HaloZyme operates through two primary business segments: Product revenues and Royalty, Contract and Other revenues. The Product segment generates revenue from the commercialization of proprietary pharmaceutical products, while the Royalty, Contract and Other segment includes revenues from licensing agreements, royalties on partnered products, and contract manufacturing services. The company's product portfolio includes treatments for various therapeutic areas, with a particular focus on dermatology and other specialty pharmaceutical markets.
The company's core technology platform centers on its proprietary Enhanze technology, which utilizes recombinant human hyaluronidase (rHuPH20) to enable subcutaneous delivery of biologics and other therapeutic agents. This technology allows for improved drug delivery, reduced injection volumes, and enhanced patient convenience compared to traditional intravenous administration methods. HaloZyme has leveraged this platform through both internal product development and strategic partnerships with major pharmaceutical companies.
HaloZyme's business model combines direct commercialization of proprietary products with a licensing and partnership approach for its drug delivery technology. The company generates revenue through product sales, royalties from licensed technologies, and contract manufacturing arrangements. This diversified approach provides multiple revenue streams and reduces dependence on any single product or partnership.
The company has pursued strategic acquisitions to expand its product portfolio and capabilities, including the acquisition of Antares Pharma, which brought established dermatology and specialty pharmaceutical products into HaloZyme's portfolio. The company maintains research and development operations focused on advancing its pipeline of novel therapeutics and expanding applications of its Enhanze technology platform.
HaloZyme operates with a global footprint, serving patients and healthcare providers across multiple geographic markets while maintaining manufacturing and operational facilities to support its commercial and development activities.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- December
- CIK
- 1159036
- SIC
- 2836
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns HALOZYME THERAPEUTICS, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · HALOZYME THERAPEUTICS, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
HALOZYME THERAPEUTICS, INC.’s bonds, as funds hold them
Funds report holding 4 issues of HALOZYME THERAPEUTICS, INC.’s debt, $387.13M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 0.58%, maturing 2027 to 2032.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do HALOZYME THERAPEUTICS, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of HALOZYME THERAPEUTICS, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in HALOZYME THERAPEUTICS, INC.'s last four quarterly filings that the numbers alone won't show?”